Is gern a good investment

**Geron Corporation (GERN) is not a good investment at this time**, and there are several reasons for this conclusion:

1. **FDA Approval Status**: Geron's drug, imetelstat, has been approved for a specific indication, which limits its potential market. The FDA approval does not guarantee commercial success, and the company's future revenue will depend on the drug's performance in the market.
2. **Financial Performance**: Geron has a negative P/E ratio, which indicates that the company is not currently profitable. The company's revenue and net income have been negative in recent years, which raises concerns about its financial health and future growth potential.
3. **Market Competition**: The blood cancer drug market is highly competitive, with several large pharmaceutical companies operating in the space. Geron faces significant competition from established players like Bristol Myers Squibb, which could impact its market share and profitability.
4. **Analyst Ratings and Price Targets**: Despite the FDA approval, analysts have set a relatively low average price target of $6.5, with a "Strong Buy" consensus rating. This suggests that analysts do not see significant upside potential in the stock.
5. **Investor Sentiment**: The stock has experienced a significant decline over the past year, and there has been no recent positive news or developments that would indicate a turnaround in investor sentiment.

In conclusion, while Geron's FDA approval is a positive step, the company's financial performance, competitive market, and low analyst price targets suggest that it is not a good investment at this time. Investors should carefully consider these factors and their own investment strategy before making a decision.